Actively hiring
Prescription Drugs
As featured in
View 1 job
Claim pageClaim
Follow
Overview
Connections
News
Salaries
Products
People
Growth
Offices
Jobs
Financials
Visa sponsorship
A-rated
Sponsor licence
Skilled Worker
Visa route
6
Open roles in United Kingdom
In the register as Norgine Limited, Hengoed, Wales
Other sponsors in the same field
See 6 open roles Alert me
UK Home Office · checked Oct 29, 2026 · Visa details by country
News
Norgine welcomes TGA registration in Australia of PEDMARQSI (sodium thiosulfate anhydrous) for the prevention of cisplatin-induced hearing loss in children1
Read more
Report
Norgine announces European Commission Marketing Authorisation for XOLREMDI (mavorixafor), the first authorised treatment for patients with WHIM syndrome in the European Union
Read more
Report
Norgine announces £23 million new investment as part of more than £50 million committed to expanding medicines manufacturing in Wales
/PRNewswire/ -- Norgine, a leading European specialty pharmaceutical company, today announced a new £23 million investment in its Hengoed, Wales manufacturing...
Read more
Report
Norgine completes acquisition of Theravia
Norgine today announced the successful completion of the acquisition of Theravia, an international pharmaceutical company specialising in therapies for patients with rare and debilitating conditions. The closure of this acquisition marks a major step forw
Read more
Report
Norgine strengthens rare disease portfolio with acquisition of Theravia
Norgine and Theravia announced today that they have entered into a definitive agreement under which Norgine will acquire Theravia, an international pharmaceutical company specialising in cutting-edge treatments for patients with rare and debilitating cond
Read more
Report
Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine DFMO) in high-risk neuroblastoma
Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB). This follows the submissions in April 2024, via Project Orbis, in Australia, Sw
Read more
Report
Growth
Hiring Momentum
93/100
Scaling fast
Open positions
14
15 opened / 17 closed in 30 days
Median time-to-fill
20 days
faster than 56% of the market
ATS activity
Every ~4 hours
Today
Hiring Dynamics
+100%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Field & Service
16% ▼
Legal
13% ▲
Finance
11% ▼
Management
11%
Sales
11%
QA
5% ▲
Actively hiring for Management (+3 in 30 days)
Activity Timeline
Added Digital Twin to stack
Oct 2026
Added ICH Guidelines to stack
Oct 2026
Added LIMS to stack
Oct 2026
Added 21 CFR Part 11 to stack
Oct 2026
Added ISO 13485 to stack
Oct 2026
Added GMP to stack
Oct 2026
Added CAPA to stack
Oct 2026
Added GCP to stack
Oct 2026
New location: Lisbon
Oct 2026
New location: Rueil-Malmaison
Oct 2026
Added Microsoft Excel to stack
Oct 2026
+3 jobs in a week
Sep 2026
Offices
Where the company hires and what each office is for
Cities
6
Hiring now
6
Countries
5
Busiest office
Hengoed
Loading the map
Headquarters
Builds here
Office with open vacancies
Tap a pin for the office
Hengoed
United Kingdom
Regional office
8 open roles 16 posted in 90 days 13% engineering 1000-5000 est. staff
hires for Finance, Sales, QA
Dreux
France
Plant / site
3 open roles 5 posted in 90 days 200-500 est. staff
hires for Field & Service
Copenhagen
Denmark
Sales office
2 open roles 3 posted in 90 days 50-200 est. staff
hires for Management, Sales
Amsterdam
Netherlands
2 open roles 2 posted in 90 days 50-200 est. staff
hires for Finance, Legal
Uxbridge
United Kingdom
1 open roles 6 posted in 90 days 200-500 est. staff
hires for Finance
Sydney
Australia
Sales office
1 open roles 1 posted in 90 days 50-200 est. staff
hires for Administrative
Earlier presence
Vienna, Austria
Leuven, Belgium
Rueil-Malmaison, France
Lisbon, Portugal
Jobs
Apply
Financials
Total raised
$29.2M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2026 | $29.2M | Details |

Abbott
AbbVie
AstraZeneca
Eli Lilly and Company